MDxHealth SA is a healthcare company that provides molecular diagnostic products for personalized cancer treatment. The company specializes in developing and commercializing innovative epigenetic tests and biomarkers for cancer diagnosis and personalized treatment. MDxHealth's products are used in the diagnosis and treatment of prostate, bladder, and colon cancers.
The company's lead product is the ConfirmMDx for Prostate Cancer test, which is a non-invasive liquid biopsy test used to detect prostate cancer in men who have had a previous negative biopsy. The test analyzes prostate tissue samples for epigenetic changes that are associated with cancer. MDxHealth also offers SelectMDx for Prostate Cancer, a urine-based test that helps identify men at an increased risk of having aggressive prostate cancer.
In addition to its prostate cancer products, MDxHealth offers the AssureMDx for Bladder Cancer test, which is a non-invasive liquid biopsy test used to detect bladder cancer in patients with hematuria, or blood in their urine. The test analyzes urine samples for the presence of bladder cancer DNA.
MDxHealth has partnerships with several pharmaceutical companies to develop companion diagnostic tests for use with their cancer therapies. The company is headquartered in Herstal, Belgium, and has offices in the United States. It is publicly traded on the Euronext Brussels stock exchange under the ticker symbol MDXH.
|
